Emerg Infect Dis. 2020 Dec;26(12):2907-2915. doi: 10.3201/eid2612.201221.
Global expansion of antimicrobial drug-resistant Escherichia coli sequence type (ST) 131 is unrivaled among human bacteria. Understanding trends among ST131 clades will help with designing prevention strategies. We screened E. coli from blood samples (n = 1,784) obtained in Calgary, Alberta, Canada, during 2006, 2012, and 2016 by PCR for ST131 and positive samples (n = 344) underwent whole-genome sequencing. The incidence rate per 100,000 residents increased from 4.91 during 2006 to 12.35 during 2012 and 10.12 during 2016. ST131 belonged to clades A (10%), B (9%), and C (81%). Clades C1-nonM27 and B were common during 2006, and C2 containing bla, C1-M27 containing bla, and A were responsible for the increase of ST131 during 2012 and 2016. C2 was the most antimicrobial drug-resistant subclade and increased exponentially over time. Eradicating ST131, more specifically the C2 subclade, will lead to considerable public health benefits for persons in Calgary.
全球范围内，耐抗生素药物的大肠杆菌序列类型 131 （ST131）的扩张在人类细菌中是无与伦比的。了解 ST131 分支的趋势将有助于设计预防策略。我们通过 PCR 对来自加拿大阿尔伯塔省卡尔加里的血液样本（2006 年、2012 年和 2016 年共 1784 份）进行 ST131 筛选，对阳性样本（344 份）进行全基因组测序。每 10 万名居民的发病率从 2006 年的 4.91 上升到 2012 年的 12.35 和 2016 年的 10.12。ST131 属于 A （10%）、B （9%）和 C （81%）分支。2006 年，C1-nonM27 和 B 分支较为常见，而 2012 年和 2016 年 C2 包含 bla、C1-M27 包含 bla 和 A 负责 ST131 的增加。C2 是最具抗药性的亚分支，并随着时间呈指数增长。根除 ST131，更具体地说，是 C2 亚分支，将为卡尔加里的民众带来可观的公共卫生效益。
